Ozmosi | NEUROTROPHIN-3 Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

NEUROTROPHIN-3

Alternative Names: neurotrophin-3, nerve growth factor 2, neurotrophic factor
Clinical Status: Active
Latest Update: 2025-12-03
Latest Update Note: News Article

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Herantis Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for NEUROTROPHIN-3

Countries in Clinic: Germany, Poland

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Parkinson's Disease

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2023-506519-16-00

 ASK-PD5-CS201

P2

Recruiting

Parkinson's Disease

2027-12-01

2025-05-02

Treatments

2017-005170-19

 Long-Term Follow-up Safety After DDS Implantation with/without CDNF Infusions

P2

Active, not recruiting

Parkinson's Disease

2023-12-30

2022-03-13

Treatments

Recent News Events

Date

Type

Title

12/03/2025

News Article

 Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

12/03/2025

News Article

 Cognito Therapeutics Announces Presentation of New CSF Proteomic and EEG Biomarker Data for Spectris™ in Alzheimer's Disease at CTAD 2025

11/26/2025

News Article

 Herantis Pharma announces successful completion of six-month GLP toxicology study of HER-096

11/05/2025

News Article

 Active Pharmaceutical Ingredients CDMO Market to Worth USD 260.98 Billion by 2034

05/15/2024

PubMed

 Posterior vitreous attachment as a risk factor for endophthalmitis following intravitreal antivascular endothelial growth factor injection.

04/10/2024

PubMed

 Sustained delivery of NT-3 and curcumin augments microenvironment modulation effects of decellularized spinal cord matrix hydrogel for spinal cord injury repair.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions